Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trospium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 12/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 11/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.97 |
| ▸ | HRH1 | P35367 | 3/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trospium SCHEMBL13836646 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL111738 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL29629492 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL25785 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL119810 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL2447242 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL724191 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL31112961 | 0.97 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL22609933 | 0.97 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL1707994 | 0.94 | CHRM3 (0.89) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3441087-B1 | METHODS OF TREATING CHRONIC PAIN | TEVA PHARMACEUTICALS INT GMBH (CH) | 2025-02-19 | — | — | EP | claimed |
| US-20260139031-A1 | FUSION PROTEIN | LEVICEPT LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| US-20260132189-A1 | Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same | TEVA PHARMACEUTICALS INT GMBH (CH) | 2026-05-14 | — | — | US | disclosed |
| US-20260115194-A1 | NEW TREATMENTS FOR PAIN | SEVENLESS THERAPEUTICS LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| EP-4719596-A1 | FUSION PROTEIN | Levicept Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720104-A1 | LOW AFFINITY P75 NEUROTROPHIC RECEPTOR EXTRACELLULAR DOMAIN FUSED TO A FC MOIETY AS NGF ANTAGONIST THERAPY OF PAIN | Levicept Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4714435-A2 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | Vertex Pharmaceuticals Incorporated (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4712967-A2 | G-PROTEIN COUPLED RECEPTOR ANTAGONIST | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4712957-A2 | ISOANDROGRAPHOLIDE ANALOGS AND METHOD FOR TREATMENT USING THE SAME | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260062459-A1 | FUSION PROTEIN | LEVICEPT LTD (GB) | 2026-03-05 | — | — | US | disclosed |
| US-20220175663-A1 | STABLE LIQUID ANTIBODY FORMULATION | PFIZER (US) | 2022-06-09 | — | — | US | disclosed |
| US-11339202-B2 | Therapeutic use of p75NTR neurotrophin binding protein | LEVICEPT LIMITED (GB) | 2022-05-24 | — | — | US | disclosed |
| US-11325902-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-05-10 | — | — | US | disclosed |
| US-20220110923-A1 | ESTERS AND CARBAMATES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2022-04-14 | — | — | US | disclosed |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-04-12 | — | — | US | disclosed |
| CN-110225911-B | Oxadiazolone transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2022-04-05 | — | — | CN | disclosed |
| US-11285304-B2 | Drug delivery devices with drug-permeable component and methods | TARIS BIOMEDICAL LLC (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3165236-B1 | METHODS FOR TREATING VISCERAL PAIN BY ADMINISTERING ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE | TEVA PHARMACEUTICALS INT GMBH (CH) | 2022-03-16 | — | — | EP | disclosed |
| CN-109476640-B | Bicyclic proline compounds | 豪夫迈·罗氏有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-20220048986-A1 | PREVENTING, TREATING, AND REDUCING (PERSISTENT) POST-TRAUMATIC HEADACHE | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048986-A1 | PREVENTING, TREATING, AND REDUCING (PERSISTENT) POST-TRAUMATIC HEADACHE | CALCA, CALCRL, OPRL1 | CHRM3 98/4885CHRM2 115/4885CHRM1 81/4885 |
| US-20260132189-A1 | Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same | CALCRL, CALCA, CALCB | CHRM3 476/4885CHRM2 189/4885CHRM1 210/4885 |
| US-20260062459-A1 | FUSION PROTEIN | NTRK2, BDNF, NGFR | CHRM3 2556/4885CHRM2 2792/4885CHRM1 2668/4885 |
| US-20260115194-A1 | NEW TREATMENTS FOR PAIN | SOS1, OPRL1, SOS2 | CHRM3 2531/4885CHRM2 3015/4885CHRM1 2262/4885 |
| US-11325902-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | CHRM3 1015/4885CHRM2 1494/4885CHRM1 1932/4885 |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | CHRM3 1003/4885CHRM2 1497/4885CHRM1 2022/4885 |
| US-20220110923-A1 | ESTERS AND CARBAMATES AS MODULATORS OF SODIUM CHANNELS | SCN10A, CACNA1A, SCN3A | CHRM3 300/4885CHRM2 803/4885CHRM1 882/4885 |
| US-20260139031-A1 | FUSION PROTEIN | NTRK2, BDNF, NGFR | CHRM3 2605/4885CHRM2 2673/4885CHRM1 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.